Nanoparticles as vehicles of heterologous epitopes

R. Cunliffe, I. Ferlenghi, M. Scarselli, A. Fantoni
GSK Vaccines, Via Fiorentina, 1, 53100 Siena, Italy, **robert-francesco.x.cunliffe@gsk.com**

Neisseria meningitidis is a major cause of sepsis and meningitis in children and adolescents. Bexsero™ is a successful multicomponent vaccine formulation against *Neisseria meningitides* serogroup B (MenB), composed of three surface-exposed meningococcal proteins. Here follows the description of a structural vaccinology approach toward the design of a more broadly cross-protective next generation Bexsero™ vaccine. Guided extensively by EM techniques, the approach sees a recombinant protein epitope displayed within a ferritin nanoparticle scaffold to elicit a more potent immune response.